Published in Mol Cell Biol on September 17, 2007
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem (2009) 1.27
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Res (2009) 1.11
Regulation of TGF-beta signalling by Fbxo11, the gene mutated in the Jeff otitis media mouse mutant. Pathogenetics (2009) 1.08
Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. Sci Rep (2013) 1.00
Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J Diabetes Res (2013) 0.97
Crosstalk between p53 and TGF-β Signalling. J Signal Transduct (2012) 0.95
Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun (2013) 0.95
The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene (2012) 0.91
SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Mol Cell Biol (2011) 0.88
CLIC4 and Schnurri-2: a dynamic duo in TGF-beta signaling with broader implications in cellular homeostasis and disease. Nucleus (2011) 0.87
Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β). J Biol Chem (2011) 0.81
TP53 drives invasion through expression of its Δ133p53β variant. Elife (2016) 0.79
Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53. Am J Cancer Res (2015) 0.78
Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway. J Biol Chem (2015) 0.77
The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation. J Pathol (2009) 0.76
Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lung. Dis Model Mech (2015) 0.75
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget (2016) 0.75
Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. J Clin Med (2016) 0.75
Surfing the p53 network. Nature (2000) 35.36
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
Wound healing--aiming for perfect skin regeneration. Science (1997) 16.08
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J (1998) 10.01
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
How cells read TGF-beta signals. Nat Rev Mol Cell Biol (2000) 8.93
Transcriptional control by the TGF-beta/Smad signaling system. EMBO J (2000) 8.49
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Controlling TGF-beta signaling. Genes Dev (2000) 8.13
TGF beta signals through a heteromeric protein kinase receptor complex. Cell (1992) 8.12
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Decision making by p53: life, death and cancer. Cell Death Differ (2003) 5.52
Gain of function mutations in p53. Nat Genet (1993) 4.19
Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell (2003) 3.45
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 3.30
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell (1984) 3.05
TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem (1997) 3.03
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene (2004) 2.30
Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol Cell Biol (1997) 2.25
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol (1991) 2.20
Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog (1993) 1.84
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene (2001) 1.80
Transcription regulation by mutant p53. Oncogene (2007) 1.78
The types II and III transforming growth factor-beta receptors form homo-oligomers. J Cell Biol (1994) 1.76
Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem (2001) 1.67
Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science (2007) 1.65
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res (2004) 1.59
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 1.32
A single internalization signal from the di-leucine family is critical for constitutive endocytosis of the type II TGF-beta receptor. J Cell Sci (2001) 1.31
Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene (2003) 1.28
Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem (2004) 1.27
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene (2006) 1.23
Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci U S A (1992) 1.20
Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-ras diffusion and signaling. Mol Cell Biol (2006) 1.18
Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds. Exp Cell Res (2004) 1.17
Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br J Cancer (1999) 1.08
Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. Cancer Res (1993) 1.07
Transforming growth factor-beta1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes. Biochem Biophys Res Commun (2002) 1.03
Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res (2006) 0.98
Nerve growth factor mediates activation of the Smad pathway in PC12 cells. Eur J Biochem (2004) 0.93
The effects of a mutant p53 protein on the proliferation and differentiation of PC12 rat phaeochromocytoma cells. J Cell Biochem (2006) 0.92
Correlated abnormalities of transforming growth factor-beta 1 response and p53 expression in thyroid epithelial cell transformation. Mol Cell Endocrinol (1991) 0.90
The p53 saga: the good, the bad, and the dead. Harvey Lect (2003) 0.88
Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait. Proc Natl Acad Sci U S A (1993) 0.87
Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res (1997) 0.81
p53 and TGF-beta in development: prelude to tumor suppression? Cell (2003) 0.78
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell (2011) 3.31
Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J Cell Biol (2002) 2.62
The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem (2001) 2.59
Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol Cell Biol (2005) 2.24
Differently anchored influenza hemagglutinin mutants display distinct interaction dynamics with mutual rafts. J Cell Biol (2003) 2.22
Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat Genet (2012) 2.20
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol Cell Biol (2004) 2.09
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol (2006) 1.99
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol (2013) 1.97
Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 1.95
Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene (2004) 1.94
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Single-cell analysis reveals that expression of nanog is biallelic and equally variable as that of other pluripotency factors in mouse ESCs. Cell Stem Cell (2013) 1.67
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. Biochem J (2003) 1.61
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol (2005) 1.60
Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med (2010) 1.60
Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res (2004) 1.59
p53, a novel regulator of lipid metabolism pathways. J Hepatol (2011) 1.58
Actomyosin-generated tension controls the molecular kinetics of focal adhesions. J Cell Sci (2011) 1.57
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
'Cancer associated fibroblasts'--more than meets the eye. Trends Mol Med (2013) 1.52
A role for the juxtamembrane cytoplasm in the molecular dynamics of focal adhesions. PLoS One (2009) 1.50
Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site. PLoS One (2007) 1.40
p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem (2004) 1.39
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res (2006) 1.33
p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis (2010) 1.33
TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat (2003) 1.30
Transforming growth factor-beta receptors interact with AP2 by direct binding to beta2 subunit. Mol Biol Cell (2002) 1.29
Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell (2007) 1.29
The heel and toe of the cell's foot: a multifaceted approach for understanding the structure and dynamics of focal adhesions. Cell Motil Cytoskeleton (2009) 1.29
Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene (2003) 1.28
Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One (2008) 1.27
On a fundamental structure of gene networks in living cells. Proc Natl Acad Sci U S A (2012) 1.21
Rac2 regulation of phospholipase C-beta 2 activity and mode of membrane interactions in intact cells. J Biol Chem (2002) 1.19
Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am (2003) 1.18
Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-ras diffusion and signaling. Mol Cell Biol (2006) 1.18
Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal (2011) 1.18
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One (2011) 1.15
Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol Metab (2012) 1.15
Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis (2008) 1.13
The role of p53 in base excision repair following genotoxic stress. Carcinogenesis (2003) 1.13
Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. BMC Syst Biol (2011) 1.13
Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics (2010) 1.10
p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res (2010) 1.08
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol (2005) 1.08
Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate. Aging (Albany NY) (2009) 1.07
Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One (2011) 1.03
Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis (2009) 1.03
Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol (2008) 1.03
Cyclodextrins but not compactin inhibit the lateral diffusion of membrane proteins independent of cholesterol. Traffic (2006) 1.03
The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis (2002) 1.02
DOC2B acts as a calcium switch and enhances vesicle fusion. J Neurosci (2008) 1.02
Differential effects of prenylation and s-acylation on type I and II ROPS membrane interaction and function. Plant Physiol (2010) 1.02
A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One (2010) 1.00
Src kinase activity and SH2 domain regulate the dynamics of Src association with lipid and protein targets. J Cell Biol (2007) 1.00
Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci (2012) 1.00